Floatz logo

Pirfenidone

Pulmonary Fibrosis

Boehringer IngelheimSmall moleculePhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Pulmonary Fibrosis cohort.

Asset / SponsorPhaseRating
N-Acetyl-L-Cysteine
Boehringer Ingelheim
Phase 3BB
Nintedanib
Boehringer Ingelheim
Phase 3BB
Admilparant
Bristol-Myers Squibb
Phase 3BB
Sildenafil
Alicia Gerke
Phase 3BB
Interferon Gamma-1B
NYU Langone Health
Phase 3BB

View all 38 →

Same molecule, other indications

Pirfenidone is also rated in:

idiopathic pulmonary fibrosisDormant
A
Indicative ·
80 / 100
View asset →
fibrotic liver diseaseDormant
B
Indicative ·
62 / 100
View asset →
liver disorderDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →